Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy

被引：11
|
作者：
Makis, William [1 ]
McCann, Karey [1 ]
Riauka, Terence A. [1 ]
McEwan, Alexander J. B. [1 ]
机构：
[1] Cross Canc Inst, Dept Diagnost Imaging, Edmonton, AB T6G 1Z2, Canada
来源：
CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 11期
关键词：
PRRT; Lu-177; DOTATATE; lutetium; glucagonoma; necrolytic migratory erythema;
D O I：
10.1097/RLU.0000000000000891
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 56-year-old man presented with a history of 2 prior resections of a recurrent pancreatic glucagonoma in the past 4 years. Workup revealed new liver and abdominal nodal metastases with a rising serum glucagon level. He was started on peptide receptor radionuclide therapy with Lu-177 DOTATATE, and his disease stabilized, while his glucagon levels decreased and also stabilized. After 4 induction and 2 maintenance cycles, he remains progression free for 23 months.
引用
收藏
页码：877 / 879
页数：3
相关论文
共 50 条
  • [1] Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2016, 41 (01) : 50 - 52
  • [2] Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy A Suggested Protocol
    Makis, William
    McCann, Karey
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2016, 41 (01) : 53 - +
  • [3] Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 880 - 884
  • [4] 177Lu DOTATATE nanoparticles: A therapeutic option for peptide receptor radionuclide therapy
    Arora, Geetanjali
    Shukla, Jaya
    Ghosh, Sourabh
    Malhotra, Arun
    Bandohpadhyaya, Guru
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [5] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02): : 177 - 182
  • [6] Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Sundin, A.
    Wassberg, C.
    Lubberink, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S223 - S224
  • [7] Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy
    Makis, William
    McCann, Karey
    Bryanton, Mark
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (12) : 962 - 964
  • [8] Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT
    Makis, William
    McCann, Karey
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (05) : E278 - E281
  • [9] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    [J]. CANCERS, 2022, 14 (23)
  • [10] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Rahul V. Parghane
    Sandip Basu
    [J]. Journal of Nuclear Cardiology, 2020, 27 : 340 - 341
12345